AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03322215
Drug: Fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 500 mg intramuscularly Days 1 and 15 of cycle 1, and then on Day 1 of each subsequent 28-days cycle.
Trial: NCT00536887
Drug: atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atorvastatin 10 mg versus 40 mg during the 8 months of follow-up
Trial: NCT03033342
Drug: Oral single doses of MRX-4
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single escalating doses of MRX-4
Trial: NCT03033342
Drug: Oral multiple doses of MRX-4
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending doses of MRX-4 given twice daily for 10 days
Trial: NCT03033342
Drug: MRX-4 co-administered with omeprazole
RxNorm normalized name: CO
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MRX-4 given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
Trial: NCT03033342
Drug: Placebo co-administered with omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
Trial: NCT02303899
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: infusion drug
Trial: NCT02303899
Drug: Imatinib mesylate
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral drug
Trial: NCT03082014
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: blood pressure lowering agent - dihydropyridine Ca2+-channel blocker
Trial: NCT03082014
Drug: Losartan
RxNorm normalized name: Losartan
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: blood pressure lowering agent - angiotensin-receptor blockers
Trial: NCT03082014
Drug: Atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: blood pressure lowering agent - beta-blocker
Trial: NCT01910870
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m² I.V. (day 1 to day 3) Total dose : 75 mg/m² every 3 weeks
Trial: NCT01238978
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT04075409
Drug: Padsevonil
RxNorm normalized name: Padsevonil
DrugBank: Padsevonil (DB14977)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Padsevonil will be administered in predefined dosages.
Trial: NCT00000514
Drug: atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000514
Drug: reserpine
RxNorm normalized name: Reserpine
DrugBank: Reserpine (DB00206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02382848
Drug: Prazosin
RxNorm normalized name: Prazosin
DrugBank: Prazosin (DB00457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
Trial: NCT02382848
Drug: Prazosin
RxNorm normalized name: Prazosin
DrugBank: Prazosin (DB00457)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A starting dose of Prazosin (1mg capsule) will be given at Week # 5 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
Trial: NCT01839656
Drug: nusinersen
RxNorm normalized name: Nusinersen
DrugBank: Nusinersen (DB13161)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered by intrathecal (IT) injection
Trial: NCT00865085
Drug: Citalopram HBr 40 mg tablets, single dose
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A: Experimental Subjects received Purepac formulated products under fasting conditions
Trial: NCT01713556
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01261169
Drug: Myfortic
RxNorm normalized name: Myfortic
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Myfortic in uveitis
Trial: NCT02383433
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT02383433
Drug: Gemcitabine Hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01256021
Drug: Botulinum Toxin Type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: 1 time, gastrocnemius muscles injection, dose of 4U/kg body weight in patients with hemiplegia, dose of 6U/kg body weight in patients with diplegia, Maximum dosage 200U
Trial: NCT03474081
Drug: Tiotropium
RxNorm normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium will be provided as a hard gelatin capsule for oral inhalation containing 18 mcg tiotropium bromide blended with lactose, administered via HANDIHALER DPI.
Trial: NCT03474081
Drug: Albuterol/salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol/salbutamol will be provided as an inhalation via MDI with a spacer or nebules and will be given as a rescue medication throughout the study.
Trial: NCT03474081
Drug: Placebo to match tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given as hard gelatin capsule for oral inhalation containing lactose, administered via HANDIHALER DPI.
Trial: NCT01274611
Drug: Botulinum Toxin Type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botox will be injected into the underarm, targeting the sweat glands, to stop underarm sweating.
Trial: NCT02301481
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 40mg/m2, orally twice daily every weekday concurrently with radiotherapy treatment
Trial: NCT02301481
Drug: SOX
RxNorm normalized name: Vasoxyl
DrugBank: Methoxamine (DB00723)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SOX (S-1: 40\~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
Trial: NCT00272116
Drug: Placebo and vitamin A single dose at enrollment
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was plain glucose. Vitamin A 100,000 IU to infants and 200,000 IU to older children
Trial: NCT03047291
Drug: Probiotic
RxNorm normalized name: PROBIOTIC
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
Trial: NCT00737594
Drug: Cobiprostone
RxNorm normalized name: Cobiprostone
DrugBank: Cobiprostone (DB05514)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobiprostone capsules for oral administration
Trial: NCT01730404
Drug: CHF6001 DPI
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01730404
Drug: Roflumilast
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01711866
Drug: Rotigotine
RxNorm normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rotigotine up to 16 mg / 24 hours, 4 weeks.
Trial: NCT00906269
Drug: Sildenafil therapy plus post-NSRRP HBO2T
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil (Viagra) 50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP hyperbaric oxygen therapy (90 minutes of 100% oxygen at 2.2ATA (equivalent to the pressure exerted at a depth of approximately 40 feet below sea level). There will be 5 or 10 treatments. The full treatment cycle will be completed within 2 weeks.
Trial: NCT00906269
Drug: Sildenafil therapy plus sham post-NSRRP HBO2T
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil (Viagra)50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP sham hyperbaric oxygen therapy - 90 minutes at 2.2ATA but instead of 100% oxygen, they will receive air administered via the oxygen hoods, as if they were being administered oxygen. Participants in this group will receive 5 or 10 sham treatment sessions. Full treatment cycle will be completed within 2 weeks.
Trial: NCT02558400
Drug: Netarsudil (AR-13324) Ophthalmic Solution 0.02%
DrugBank: Netarsudil (DB13931)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)
Trial: NCT02558400
Drug: Latanoprost Ophthalmic Solution 0.005%
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 drop once daily (QD), in the evening (PM) in both eyes (OU)
Trial: NCT00651963
Drug: ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe 10 mg daily was added during 4 weeks.~The patients continued taking their usual Statin without titrating the dose.
Trial: NCT00973882
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin AUC4 on day 1 repeated every 3 weeks for a maximum of 6 cycles
Trial: NCT00973882
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 100 mg/m2 on day 1, day 2 and day 3 repeated every 3 weeks for a maximum of 6 cycles
Trial: NCT00265070
Drug: Gefitinib
RxNorm normalized name: Gefitinib
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg tablet oral daily dose
Trial: NCT00459537
Drug: terbinafine hydrogen chloride
DrugBank: Terbinafine (DB00857)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 % terbinafine hydrogen chloride (HCL)
Trial: NCT00459537
Drug: amorolfine nail lacquer
RxNorm normalized name: amorolfine
DrugBank: Amorolfine (DB09056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 % amorolfine nail lacquer
Trial: NCT04593459
Drug: Metformin Hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: See Arm description
Trial: NCT04608734
Drug: Buccal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The drug was sprayed in the buccal vestibule across the area between the primary first and second molars in all four quadrants to maximize the absorption through wide area of the buccal mucosa.
Trial: NCT04608734
Drug: Intranasal midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Half of the dose was sprayed in the right nostril and the other half in the left nostril to double the absorptive surface area by short and quick puffs.
Trial: NCT00242307
Drug: Roflumilast
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01075984
Drug: Posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01075984
Drug: Dextrose 5% in water
RxNorm normalized name: LVP solution Dextrose 5% in Water intravenous solution
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00456599
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1, 8, and 15 of a treatment cycle.
Trial: NCT00456599
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin 85mg/m2 will be infused following gemcitabine over approximately 90 minutes on days 1 and 15 of a treatment cycle.
Trial: NCT04295863
Drug: Nivolumab Standard
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For patients on standard schedule dosing of nivolumab, therapy will consist of 240mg IV once every 2 weeks or 480mg IV once every 4 weeks
Trial: NCT04295863
Drug: Pembrolizumab Standard
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For patients on standard schedule dosing of pembrolizumab, therapy will consist of 200mg IV once every 3 weeks or 400mg IV once every 6 weeks
Trial: NCT04295863
Drug: Nivolumab Extended
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For patients on extended interval dosing of nivolumab therapy will consist of 240mg IV once every 4 weeks or 480mg IV once every 8 weeks
Trial: NCT04295863
Drug: Pembrolizumab Extended
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For patients on extended interval dosing of pembrolizumab therapy will consist of 200mg IV once every 6 weeks
Trial: NCT02530996
Drug: BH4
RxNorm normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BH4 10 mg/kg/day given once to a total of 12 SSc patients
Trial: NCT00425490
Drug: sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00805064
Drug: triamcinolone and bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00354666
Drug: GSK159797
RxNorm normalized name: GSK159797
DrugBank: GSK159797 (DB05043)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00221494
Drug: citalopram + tiodothyronine, or + pindolol, or + placebo
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00896441
Drug: Citalopram
RxNorm normalized name: Citalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Refer to Detailed Description Section for full description of intervention. Week 1 (baseline): Subject will complete several tests to assess the subject's memory and concentration. Following visit, they will begin treatment with the antidepressant citalopram.~Week 1 MRI: Subject will have their first MRI. Week 2 visit: Physician will meet with they to assess the subject's overall condition.~Week 2 MRI: Subject will have the subject's second MRI. Week 4 visit: The study physician will meet with the subject to assess their overall condition.~Week 6 (Telephone check-in): The study physician will check in with the subject by telephone to assess the subject's overall condition.~Week 8: (End-of-study visit) Subject will take repeated tests of memory and concentration. The study physician will also discuss recommendations for further treatment of the subject's depression.~Week 8 MRI: Around the time of the subject's week 8 visit they will have the subject's third and final MRI.
Trial: NCT03561935
Drug: Propafenone
RxNorm normalized name: Propafenone
DrugBank: Propafenone (DB01182)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prescribing propafenone for the management of premature ventricular complex
Trial: NCT03561935
Drug: Indenol
RxNorm normalized name: Indenolol
DrugBank: Indenolol (DB08952)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prescribing indenol for the management of premature ventricular complex
Trial: NCT00359723
Drug: methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02313883
Drug: PerioSept(r)
RxNorm normalized name: R-348
DrugBank: R-348 (DB06321)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties
Trial: NCT02048371
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
Trial: NCT02120703
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregablin 75 mg per oral two times a day
Trial: NCT02120703
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 200 mg twice daily per oral
Trial: NCT02967939
Drug: DA-2802
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DA-2802 319mg tablet qd + placebo tablet matching to Viread® 300mg.
Trial: NCT00240110
Drug: Valproate
RxNorm normalized name: Valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproate with dose titration to achieve blood levels within the therapeutic range
Trial: NCT00240110
Drug: Lithium Carbonate
RxNorm normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants were started and stabilized on lithium carbonate as a standard treatment for bipolar disorder
Trial: NCT00469326
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: two days 80mg atorvastatin pre-treatment before PCI
Trial: NCT00109356
Drug: AQ4N (Chemotherapy)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01722292
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered IV
Trial: NCT01722292
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered IV
Trial: NCT01417364
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg. IM weekly throughout study
Trial: NCT01417364
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg IM weekly for one month alternating with placebo injections for one month throughout the study
Trial: NCT03353103
Drug: Sodium fluoride F-18 PET imaging
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: prior to surgical endarterectomy each patient will undergo sodium fluoride F-18 PET imaging
Trial: NCT00411190
Drug: Relacatib
RxNorm normalized name: Relacatib
DrugBank: Relacatib (DB06367)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will administer 60 or 120 mg tablets in Session 2
Trial: NCT00411190
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin will be administered orally
Trial: NCT01278407
Drug: Donepezil 5 mg
RxNorm normalized name: donepezil 5 mg oral tablet
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg
Trial: NCT01278407
Drug: Donepezil 10 mg
RxNorm normalized name: donepezil 10 mg oral tablet
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg and then the dose was increased to 10 mg
Trial: NCT01278407
Drug: Donepezil matched placebo
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00885794
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 intravitreal injection every 5 weeks
Trial: NCT02234921
Drug: Imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod cream (5%, 250 mg) will be self-applied topically for 5 consecutive days by patients to a 4 x 5-cm outlined area of healthy extremity skin starting on the day of the second vaccine and again during each additional vaccine cycle.
Trial: NCT02239146
Drug: catridecacog
RxNorm normalized name: Catridecacog
DrugBank: Catridecacog (DB09310)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Single doses of rFXIII administered intravenously (i.v.) to eight subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
Trial: NCT01596335
Drug: TA-650
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA-650 at 5 mg per kg body weight on the day of TA-650 administration (day 0) is administered by intravenous infusion slowly over at least 2 hours.
Trial: NCT01596335
Drug: Polyethylene Glycol-treated Human Immunoglobulin (VGIH)
RxNorm normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VGIH at 2 g per kg body weight on the day of VGIH administration (day 0) is administered by intravenous infusion slowly over at least 20 hours.